Nonalcoholic fatty liver disease - PubMed (original) (raw)
Review
. 2006 Jun 1;73(11):1961-8.
Affiliations
- PMID: 16770927
Free article
Review
Nonalcoholic fatty liver disease
Max Bayard et al. Am Fam Physician. 2006.
Free article
Abstract
Nonalcoholic fatty liver disease is a common condition associated with metabolic syndrome. It is the most common cause of elevated liver enzymes in U.S. adults, and is diagnosed after ruling out other causes of steatosis (fatty infiltration of liver), particularly infectious hepatitis and alcohol abuse. Liver biopsy may be considered if greater diagnostic and prognostic certainty is desired, particularly in patients with diabetes, patients who are morbidly obese, and in patients with an aspartate transaminase to alanine transaminase ratio greater than one, because these patients are at risk of having more advanced disease. Weight loss is the primary treatment for obese patients with nonalcoholic fatty liver disease. Medications used to treat insulin resistance, hyperlipidemia, and obesity have been shown to improve transaminase levels, steatosis, and histologic findings. However, no treatments have been shown to affect patient-oriented outcomes.
Similar articles
- Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
Tilg H, Moschen A. Tilg H, et al. Minerva Gastroenterol Dietol. 2010 Jun;56(2):159-67. Minerva Gastroenterol Dietol. 2010. PMID: 20485253 Review. - Nonalcoholic fatty liver disease.
Adams LA, Angulo P, Lindor KD. Adams LA, et al. CMAJ. 2005 Mar 29;172(7):899-905. doi: 10.1503/cmaj.045232. CMAJ. 2005. PMID: 15795412 Free PMC article. Review. - Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children.
Lee YS, Kek BL, Poh LK, Saw SM, Loke KY. Lee YS, et al. J Pediatr Gastroenterol Nutr. 2008 Aug;47(2):172-8. doi: 10.1097/MPG.0b013e318162a0e5. J Pediatr Gastroenterol Nutr. 2008. PMID: 18664869 - Alcoholic and nonalcoholic forms of fatty liver disease.
Forgione A, Miele L, Cefalo C, Gasbarrini G, Grieco A. Forgione A, et al. Minerva Gastroenterol Dietol. 2007 Mar;53(1):83-100. Minerva Gastroenterol Dietol. 2007. PMID: 17415346 Review. - Nonalcoholic fatty liver disease.
Hjelkrem MC, Torres DM, Harrison SA. Hjelkrem MC, et al. Minerva Med. 2008 Dec;99(6):583-93. Minerva Med. 2008. PMID: 19034256 Review.
Cited by
- Senescence Marker Protein 30: Functional and Structural Insights to its Unknown Physiological Function.
Scott SH, Bahnson BJ. Scott SH, et al. Biomol Concepts. 2011 Dec 1;2(6):469-480. doi: 10.1515/BMC.2011.041. Epub 2012 Jul 24. Biomol Concepts. 2011. PMID: 22844387 Free PMC article. - Therapeutic targets in the ASK1-dependent stress signaling pathways.
Hayakawa R, Hayakawa T, Takeda K, Ichijo H. Hayakawa R, et al. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(8):434-53. doi: 10.2183/pjab.88.434. Proc Jpn Acad Ser B Phys Biol Sci. 2012. PMID: 23060232 Free PMC article. Review. - Inflammation and Metabolic Complications in HIV.
Bourgi K, Wanjalla C, Koethe JR. Bourgi K, et al. Curr HIV/AIDS Rep. 2018 Oct;15(5):371-381. doi: 10.1007/s11904-018-0411-2. Curr HIV/AIDS Rep. 2018. PMID: 30058057 Review. - The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.
Yoon JH, Yang HJ, Kim JH, Doo SW, Yang WJ, Hwang J, Hong SS, Park S, Cho DY. Yoon JH, et al. Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E868-72. doi: 10.5489/cuaj.2395. Epub 2015 Dec 14. Can Urol Assoc J. 2015. PMID: 26788237 Free PMC article. - Non-alcoholic fatty liver disease in 2015.
Ahmed M. Ahmed M. World J Hepatol. 2015 Jun 18;7(11):1450-9. doi: 10.4254/wjh.v7.i11.1450. World J Hepatol. 2015. PMID: 26085906 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources